Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to 29.66%.

  • Collegium Pharmaceutical's EBITDA Margin rose 77900.0% to 29.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 20.74%, marking a year-over-year decrease of 115500.0%. This contributed to the annual value of 26.91% for FY2024, which is 25500.0% down from last year.
  • Collegium Pharmaceutical's EBITDA Margin amounted to 29.66% in Q3 2025, which was up 77900.0% from 18.67% recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's EBITDA Margin peaked at 41.2% during Q4 2023, and registered a low of 124.71% during Q4 2021.
  • Moreover, its 5-year median value for EBITDA Margin was 19.78% (2021), whereas its average is 13.0%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -1443700bps in 2021, then surged by 1337800bps in 2022.
  • Collegium Pharmaceutical's EBITDA Margin (Quarter) stood at 124.71% in 2021, then skyrocketed by 107bps to 9.07% in 2022, then skyrocketed by 354bps to 41.2% in 2023, then crashed by -49bps to 20.95% in 2024, then skyrocketed by 42bps to 29.66% in 2025.
  • Its EBITDA Margin was 29.66% in Q3 2025, compared to 18.67% in Q2 2025 and 12.2% in Q1 2025.